Hyderabad-primarily based Hetero and the Russian Direct Investment Fund (RDIF) are aiming to get started production of Sputnik V in India at the starting of 2021. (Reuters image)
Coronavirus vaccine in India: Russia has agreed to get started production of its Covid-19 vaccine candidate Sputnik V in India, Sputnik V has announced on Twitter. An agreement has been reached in between Russia’s sovereign wealth fund and Indian pharmaceutical firm Hetero Drugs. More than one hundred million (10 crore) doses of Sputnik V vaccine against Covid-19 will be made annually, as per a Reuters report.
Hyderabad-primarily based Hetero and the Russian Direct Investment Fund (RDIF) are aiming to get started production of Sputnik V in India at the starting of 2021. Notably, RDIF has been backing the Sputnik vaccine and marketing and advertising it globally.
Meanwhile, Phase 2 and Phase 3 human trials of Sputnik V are currently going on in India, the statement on the Sputnik V Twitter account mentioned. Drugmaker Dr. Reddy’s Laboratories Ltd has mentioned it was expecting phase 3 clinical trials to be completed by as early as March 2021.
Earlier in November, the Russian Direct Investment Fund claimed that the Sputnik V vaccine is 92 per cent powerful at guarding people today from COVID-19 according to interim trial final results, the Reuters report mentioned.
Russia also mentioned it was aiming to generate mainly freeze-dried Sputnik V coronavirus vaccine doses by the spring, a major official mentioned, eliminating the need to have for transport at ultra-low temperatures as aspect of an ambitious strategy to inoculate its population. Russia has been testing a version that has undergone lyophilisation, turning the liquid vaccine into a dry, white mass that can be stored at standard fridge temperatures of 2 to 8 degrees Celsius (35.6-46.4°F). It is then diluted prior to injection.